Sen-Jam Pharmaceutical Introduces Innovative Patent to Combat Obesity and Metabolic Disorders

Groundbreaking Patent Submission by Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical, recognized for its innovative approach in anti-inflammatory care, has filed a significant new patent application that aims to tackle obesity and metabolic disorders. The newly proposed method combines a mast cell stabilizer, H1-antihistamines, and non-steroidal anti-inflammatory drugs (NSAIDs) to combat chronic low-grade inflammation, a key contributor to various metabolic dysfunctions.

Chronic inflammation is often exacerbated by unhealthy eating habits, stress, and various lifestyle choices, leading to conditions such as obesity and diabetes. This innovative therapeutic plan created by Sen-Jam seeks to not only address these inflammatory issues but also enhance existing treatments, particularly GLP-1 receptor agonists, thereby providing potential benefits in managing weight, improving insulin resistance, and lowering inflammation throughout the system.

Jackie Iversen, Co-Founder and Chief Clinical Officer at Sen-Jam Pharmaceutical, stated, "Our approach marks a crucial advancement in addressing obesity and metabolic disorders. We aim to mitigate symptoms by tackling underlying inflammation without disrupting the body's natural defenses, which can ultimately signal a transformative shift in treatment methods for millions around the world."

The details of the patent highlight a combination therapy that significantly reduces focused inflammatory markers, such as C-reactive protein (CRP), while also modulating key cytokines linked to metabolic disorders. Additionally, the potential for synergistic effects when this therapy is combined with GLP-1 receptor agonists, may lead to improved weight loss outcomes, enhanced insulin sensitivity, and a decrease in associated cardiovascular risks.

Dr. Francis Farraye, an Advisory Board Member for Sen-Jam and a Professor of Medicine at the Mayo Clinic, emphasized, "Chronic inflammation and metabolic disorders are interconnected; however, many existing treatments fail to comprehensively address this vital relationship. Sen-Jam's approach could pave the way for addressing these conditions more effectively."

This patent submission strengthens Sen-Jam's intellectual property portfolio and highlights the company's commitment to driving scientific innovation within the inflammatory care space. Given the potential market impact, worth approximately $150 billion in metabolic and obesity therapeutics, Sen-Jam continues to redefine treatment methodologies for inflammation-related diseases.

"We see this patent as an exciting development not just for our organization but for individuals struggling with metabolic issues. It reflects a significant step forward in how the pharmaceutical industry approaches conditions linked to inflammation," Iversen added.

As part of their strategic efforts, the Sen-Jam executive team will be participating in the upcoming JPMorgan Healthcare Conference in San Francisco. During this event, they plan to engage with investors and industry leaders, discussing ways to fast-track the development and commercialization of this novel therapy. Interested parties can find additional information and explore opportunities for collaboration at wefunder.com/senjam.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is at the forefront of revolutionizing inflammatory care through its unique PAIR (Pleiotropic Anti-Inflammatory Remedies) technology. This innovative system redefines treatments by directly targeting the sources of inflammation, integrating unique combination therapies that align with the body's natural capabilities. Focused on chronic low-grade inflammation, Sen-Jam strives to deliver breakthrough solutions for obesity, metabolic disorders, and other ailments rooted in inflammation. With goals centered around enhancing vitality and longevity, Sen-Jam seeks to redefine health-care innovation to address the needs of patients globally.

For more details, please contact:
Christine Leonard
Email: [email protected]
Phone: 781-913-1902

Source: Sen-Jam Pharmaceutical